To address this gap in the literature, our study investigated the radiosensitizing effect of the ATM inhibitor AZD0156, ATR inhibitor AZD6738, and PARP inhibitor olaparib on human breast cancer cells, utilizing single-dose and fractionated radiotherapy. Here, ATR is linked to breast carcinoma.